Русский
Characteristics of exanthemas in adult-onset COVID-19
DOI: https://dx.doi.org/10.18565/epidem.2020.10.4.93-5
Ruzhentsova T.A., Khavkinа D.A., Chuklyaev P.V., Garbuzov A.A., Meshkova N.A.
1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University); Moscow, Russia
Materials and methods. 210 case histories of patients aged 18 to 96 years with confirmed coronavirus infection caused by SARS-CoV-2 virus were analyzed. All patients received standard therapy according to temporary guidelines, and other medications as indicated.
Results. Skin manifestations were observed in 11 patients. Rashes appeared in patients in the range from 1 to 10 days from the onset of the disease, while urticary and macular-papular rashes were noted at an earlier time – up to 7 days, and hemorrhagic rashes-on the 5th –10th day. The duration of exanthema ranged from 3 to 14 days, with the longest remaining hemorrhagic elements of the rash. The use of enterosorbents in toxicoderma of infectious and medicinal origin is justified and significantly improves the prognosis.
Conclusion. Exanthema was observed in COVID-19 in 5.2% of adult patients. The most frequent was urticarial rash (2.9%) and less – macula-papular 2 (1%) and hemorrhagic-type purpura and vesicles with hemorrhagic content – at the 3 (1.4%). Hemorrhagic elements of the rash were detected in patients with a more severe course. The use of enterosorbents suspends the spread of exanthema, prevents the appearance of new rash elements. Zosterin Ultra 60% is recommended as detoxification and enterosorption therapy for COVID-19, including the development of exanthemums, especially for patients with complaints of constipation that provoke other sorbents.
Literature
1. Galván Casas C., Català A., Carretero Hernández G., Rodríguez-Jiménez P., Fernández Nieto D, Rodríguez-Villa Lario А. et. al. Classification of the cutaneous manifestations of COVID -19: a rapid prospective nationwide consensus study in Spain with 375 cases. Brit. J. Dermatol. 2020. https://doi.org/10.1111/bjd.19163 2. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J. Eur. Acad. Dermatol. Venereol. 2020; 34: e212–3. doi:10.1111/jdv. 16387. 3. Tang K., Wang Y., Zhang H., Zheng Q., Fang R., Sun Q. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A brief review [published online ahead of print, 2020 May 7]. Dermatol. Ther. 2020; e13528. doi:10.1111/dth.13528 4. Вялов С.С. Нарушение проницаемости слизистой оболочки как фактор патогенеза функциональных нарушений желудочно-кишечного тракта: обоснование и возможности коррекции. Consilium Medicum 2018; (12): 99–104. Vyalov S.S. [Violation of mucosal permeability as a factor of pathogenesis of functional disorders of the gastrointestinal tract: justification and possibilities of correction]. Consilium Medicum2018; (12): 99–104. (In Russ.).
About the Autors
Tatiana A. Ruzhentsova, МD, Head, Сlinical Research Department; Рrofessor, Educational Center, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: ruzhencova@gmail.com; ORCID: http://orcid.org/0000-0002-6945-2019
Daria А. Khavkina, Statistic, Сlinical Research Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: havkina@gmail.com; ORCID: http://orcid. org/0000-0001-5919-9841
Pavel V. Chukhliaev, Methodist, Сlinical Research Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: pafachka@gmail.com, ORCID: http://orcid. org/0000-0003-1210-1215
Alexandr A. Garbuzov, Methodist, Сlinical Research Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: os.vertebra@gmail.com; ORCID: http://orcid. org/0000-0002-3378-8418
Natalia A. Meshkova, 3rd-year student, N.F. Filatov Clinical Institute of Children’s Health, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenovskiy University); Moscow, Russia; e-mail: nataliaandreevnamesh@gmail.com; ORCID: http://orcid.org/ 0000-0003-3904-7108
Similar Articles
